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Abstract N-terminal pyroglutamate (pGlu) formation from
glutaminyl precursors is a posttranslational event in the process-
ing of bioactive neuropeptides such as thyrotropin-releasing hor-
mone and neurotensin during their maturation in the secretory
pathway. The reaction is facilitated by glutaminyl cyclase (QC),
an enzyme highly abundant in mammalian brain. Here, we de-
scribe for the ¢rst time that human and papaya QC also cata-
lyze N-terminal glutamate cyclization. Surprisingly, the enzy-
matic Glu1 conversion is favored at pH 6.0 while Gln1 con-
version occurs with an optimum at pH 8.0. This unexpected
¢nding might be of importance for deciphering the events lead-
ing to deposition of highly toxic pyroglutamyl peptides in amy-
loidotic diseases.
* 2004 Published by Elsevier B.V. on behalf of the Federation
of European Biochemical Societies.
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1. Introduction
Regulatory peptides such as gonadotropin-releasing hor-
mone (GnRH), thyrotropin-releasing hormone (TRH) and
neurotensin, and the cytokines MCP-1^4, require N-terminal
pyroglutamate in order to exert their respective biological
functions [1,2]. Early studies have suggested that the forma-
tion of pyroglutamate at the N-terminus of Gln1 peptides was
a spontaneous reaction [3]. Glutaminyl cyclase (QC; EC
2.3.2.5), however, was identi¢ed to be the responsible physio-
logical catalyst (Scheme 1) [4^7].
The ¢rst QC was isolated by Messer from the latex of the
tropical plant Carica papaya in 1963 [4]. Later, in 1987, a
corresponding enzymatic activity was discovered in animal
pituitary. This mammalian QC was shown to convert the
Gln1 precursors of TRH and GnRH into the appropriate
mature pyroglutamic acid (pGlu1) peptides [5,7]. In addition,
QC was co-localized to the secretory pathway of the bovine
pituitary together with its putative products of catalysis, sup-
porting its processing role in peptide hormone biosynthesis
[8].
Coincidentally, in several neurodegenerative disorders pyro-
glutamate-containing peptides are thought to contribute to
the pathogenesis by enhancing the proteolytic stability and
neurotoxicity of hydrophobic, plaque-forming peptides [9].
The most prominent severe dementia, Alzheimer’s disease
(AD), is characterized by abnormal accumulation of extracel-
lular amyloid plaques [10^12]. Amyloid-L (AL) peptides are
generated by proteolytic processing of the L-amyloid precur-
sor protein (APP), which is cleaved N-terminally by L-secre-
tase and C-terminally by Q-secretase in a subsequent step [13].
Interestingly, within the core of amyloid plaques there exists
a dominant fraction of AL peptides containing N-terminal
pGlu, e.g. pGlu3-AL(3^40/42) and pGlu11-AL(11^40/42).
These shortened peptides are reported to be more neurotoxic
and to aggregate more rapidly than the full-length isoforms in
vitro [9,14^16].
Moreover, among all prominent AL peptides, the isoforms
containing pyroglutamate at position 3 represent the most
abundant (V50% of total AL protein) of the N-terminally
truncated peptide species [17^23]. This accumulation of
pGlu-AL peptides is likely due to the structural modi¢cation
that enhances aggregation and confers resistance to most ami-
nopeptidases [15^20,24,25].
In order to prove whether QC is a candidate enzyme able to
recognize and to turn over AL-derived peptides, we synthe-
sized and investigated Gln3-AL(1^11)a, AL(3^11)a, Gln3-
AL(3^11)a, AL(3^21)a, Gln3-AL(3^21)a and Gln3-AL(3^40)
as potential substrates of the enzyme. Another objective of
the study was to compare the fate of the AL-derived peptides
using QC in combination with an aminopeptidase, under the
rationale that aminopeptidase cleavage of full-length AL pep-
tide is a prerequisite for QC cyclization of Glu/Gln at position
3 from the N-terminus. Finally, it was of interest whether such
QC processing of the above AL peptides can be suppressed by
recently characterized QC inhibitors [26].
2. Materials and methods
2.1. Enzymes
Human QC was expressed in Pichia pastoris or Escherichia coli and
puri¢ed as described [27]. Papaya QC was puri¢ed from papaya latex
essentially as described elsewhere [28]. Puri¢ed porcine dipeptidyl pep-
tidase IV (DPIV) and pituitary homogenate were gifts from M. Wer-
mann and L. Wagner (Probiodrug).
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2.2. Oligopeptide synthesis
AL peptide fragments Gln3-AL(1^11)a, AL(3^11)a, Gln3-AL(3^11)a,
AL(3^21)a and Gln3-AL(3^21)a were synthesized as C-terminal
amides both semi-automatically in a 0.5 mmol scale on a peptide
synthesizer (Labortec SP650, Bachem) as previously described [27]
or using a Symphony peptide synthesizer (Rainin Instruments) in a
50 Wmol scale on NovaSyn0TGR resin (0.23 mmol/g). AL peptide
Gln3-AL(3^40) was synthesized in 25 Wmol scale on Fmoc-Val-Nova-
Syn0TGA resin (0.15 mmol/g). Preparative high performance liquid
chromatography (HPLC) was performed with a gradient of acetoni-
trile in water (20^65% acetonitrile over 40 min) on a 250-20 Luna
RP18 column (Phenomenex). Peptide purity and identity was con-
¢rmed by analytical HPLC and electrospray ionization mass spec-
trometry.
2.3. Assays of QC
QC activity was evaluated spectrophotometrically and £uorometri-
cally at 30‡C [27^29]. Glu-2-naphthylamine (LNA) was employed for
observation of glutamate cyclization catalyzed by papaya QC. Spon-
taneous cyclization of Glu-LNA and Gln-LNA (2.0 mM) was inves-
tigated for 30 days in 20 mM MES bu¡er, pH 6.0, 30‡C. Samples
were removed for determination of pGlu content, diluted 10-fold and
Scheme 1. N-terminal cyclization of glutaminyl peptides by QC.
Fig. 1. A: Mass spectra of Gln3-AL(1^11)a incubated with DPIV catalyzing the N-terminal truncation yielding Gln3-AL(3^11)a. B: Mass spec-
tra of Gln3-AL(1^11)a incubated with DPIV and the DPIV inhibitor Val-pyrrolidide preventing N-terminal truncation of the peptide. C: Mass
spectra of Gln3-AL(3^11)a incubated with porcine pituitary homogenate catalyzing the formation of pGlu3-AL(3^11)a. D: Mass spectra of
Gln3-AL(3^11)a incubated with QC and the QC inhibitor 1,10-phenanthroline preventing the formation of pGlu3-AL(3^11)a.
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analyzed £uorometrically [28]. For pH dependence studies the bu¡er
contained 0.05 M acetic acid, 0.05 M pyrophosphoric acid and 0.05 M
Tricine. Constant ionic strength and appropriate pH were maintained
by addition of NaCl and NaOH, respectively. Enzyme kinetic data
were analyzed using Gra¢t software (Erithacus Software).
2.4. MALDI-TOF mass spectrometry
Matrix-assisted laser desorption/ionization mass spectrometry was
carried out using a Hewlett-Packard G2025 system. Reactions using
the Gln peptides were performed in samples of 100 Wl consisting of
QC (0.01^1.0 U) and 0.5 mM substrate in 0.04 M Tris^HCl, pH 8.0,
at 30‡C or at pH and bu¡er conditions described below. At the times
indicated, samples were removed, diluted with matrix and analyzed as
described previously [27].
For long-term testing of Glu1 cyclization, AL-derived peptides
were incubated in 100 Wl 0.1 M sodium acetate bu¡er, pH 5.2
or 0.1 M Bis-Tris bu¡er, pH 6.5 at 30‡C. Peptides were applied
in 0.5 mM AL(3^11)a and other synthetic peptides or 0.15 mM
AL(3^21)a concentrations, and 0.2 U QC was added all 24 h. In the
case of AL(3^21)a, the assays contained 1% dimethylsulfoxide
(DMSO). At the times indicated in Figs. 1^3, samples were removed
from the assay tube, peptides were extracted using ZipTips (Milli-
pore), mixed with matrix solution (1:1 v/v) and subjected to mass
spectrometry. Negative controls contained either no QC or heat-
deactivated enzyme. For the inhibitor studies the sample composition
was the same as described above, with the exception of the inhibitory
compound added (5 mM benzimidazole or 2 mM 1,10-phenanthro-
line).
Fig. 2. A,B: Mass spectra of Glu3-AL(3^11)a and Glu3-AL(3^21)a incubated with recombinant human QC which was boiled for 10 min before
use. C,D: Mass spectra of Glu3-AL(3^11)a and Glu3-AL(3^21)a in the presence of active human QC resulting in the formation of pGlu3-AL(3^
11)a and pGlu3-AL(3^21)a, respectively. E,F: Mass spectra of Glu3-AL(3^11)a and Glu3-AL(3^21)a in the presence of active QC and 5 mM
benzimidazole suppressing the formation of pGlu3 formation.
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3. Results
3.1. Turnover of Gln3-AL peptides 3^11a, 3^21a and 3^40 by
recombinant human QC
All Gln3-AL-derived peptides tested were e⁄ciently con-
verted by human QC into the corresponding pGlu peptides
(Table 1). Due to the poor solubility of Gln3-AL(3^21)a and
Gln3-AL(3^40) in aqueous solution, 1% DMSO was added.
The higher solubility of Gln3-AL(3^11)a, however, allowed
kinetic analysis in both the presence and absence of DMSO
(Table 1). Taken together, the investigation of the AL peptides
as QC substrates with chain lengths of 8, 18 and 37 amino
acids (see Table 1) con¢rmed that human QC activity in-
creases with the length of its substrates. Accordingly, Gln1-
gastrin, Gln1-neurotensin, Gln1-GnRH are among the best
QC substrates [29]. Similarly, Gln3-AL(3^40) and glucagon,
the largest QC substrates investigated thus far, are cyclized
highly speci¢cally, even in the presence of 1% DMSO (Table
1). Therefore, due to better solubility and experimental hand-
ling, the further investigations concerning N-terminal process-
ing of these peptides were performed using the smaller frag-
ments of AL, Gln3-AL(1^11)a, Gln3-AL(3^11)a, AL(3^11)a
and AL(3^21)a.
3.2. Processing of Gln3-AL(1^11)a by puri¢ed DPIV and QC
present in porcine pituitary homogenate
During posttranslational processing of APP, N-terminal
degradation of the resulting AL peptide(s) occurs until the
decomposition is halted by formation of N-terminal pGlu in
vivo [16^22]. Since full-length AL(1^42) starts with the dipep-
tide Asp-Ala (a DPIV-recognition sequence) before Glu/Gln
in position 3, we investigated whether puri¢ed DPIV or ami-
nopeptidases of porcine pituitary homogenate were able to
remove this sequence from our sample peptides. Incubation
of the model peptides Gln3-AL(1^11)a with DPIV and Gln3-
AL(3^11)a with porcine pituitary homogenate resulted in the
formation of Gln3-AL(3^11)a and pGlu3-AL(3^11)a, respec-
tively (see Fig. 1A,C). When the reaction was conducted in
the presence of the DPIV inhibitor Val-pyrrolidide, no turn-
over of Gln3-AL(1^11)a was observed (Fig. 1B). Similarly, in
the presence of the QC inhibitor 1,10-phenanthroline, no ¢nal
pGlu3-AL(3^11)a formation occurred (Fig. 1D).
3.3. Turnover of AL(3^11)a and AL(3^21)a by recombinant
human QC
The incubation of AL(3^11)a and AL(3^21)a in the presence
of QC revealed that glutamate-containing peptides can also
serve as QC substrates (Fig. 2C,D). The formation of pGlu3-
AL(3^11)a and pGlu3-AL(3^21)a was investigated at pH 5.2
and 6.5, respectively. If the QC inhibitor benzimidazole was
added to the solution before starting the assay by QC addi-
tion, substrate conversion was suppressed (Fig. 2E,F). If QC
was boiled before addition, formation of the pGlu peptides
was negligible (Fig. 2A,B). No turnover was detected at basic
pH values.
3.4. pH dependence of the papaya QC-catalyzed cyclization of
Gln-LNA and Glu-LNA
The plant QC from C. papaya, an analogous but non-ho-
mologous enzyme of the mammalian QCs, has been shown to
possess similar catalytic properties to human QC, as revealed
by the substrate speci¢city pattern and pH dependence of ca-
talysis [29]. Accordingly, plant QC cyclized AL(3^11)a at pH
5.2 (not shown). In contrast to human QC, however, it readily
converts the £uorogenic substrate Glu-LNA allowing a
coupled £uorometric assay [28]. Papaya QC converted Glu-
LNA in a concentration range up to 2 mM in accordance with
Michaelis^Menten kinetics (not shown). Hence, papaya QC
was used to study the pH dependence of the conversion of
Glu-LNA and Gln-LNA. These model reactions were inves-
tigated under ¢rst-order rate-law conditions using higher en-
zyme amounts (Fig. 3). As expected the cyclization of gluta-
mine has a pH optimum at pH 8.0. In contrast, the cyclization
of glutamic acid showed a pH optimum of pH 6.0. While the
speci¢city constants at the respective pH optima di¡er ap-
proximately 80 000-fold, the ratio of QC versus glutamyl cy-
clase (EC) activity around pH 6.0 is only about 8000. The
non-enzymatic pGlu formation from Gln-LNA, investigated
at pH 6.0, was followed for 4 weeks and revealed a ¢rst-order
rate constant of 1.2U1037 s31. However, during the same
time period, no pGlu-LNA was formed from Glu-LNA en-
abling the estimation of a limiting rate constant for turnover
of 1.0U1039 s31.
4. Discussion
Since formation of pGlu1 peptides such as pGlu3-AL(3^40)
occurs neither in vitro nor in vivo spontaneously, only the
enzymatic cyclization of e.g. Glu-AL by a putative EC is con-
Fig. 3. pH dependence of the conversion of Gln-LNA (a) and Glu-
LNA (E) by papaya QC, determined under ¢rst-order rate-law con-
ditions (SIKM). Substrate concentration were 0.01 mM and 0.25
mM, respectively. The data were ¢tted to equations that account
for two dissociating groups revealing pKa values of 6.91S 0.02 and
9.5S 0.1 for Gln-LNA and 4.6S 0.1 and 7.55S0.02 for Glu-LNA.
The pKa values of the respective substrate amino groups, deter-
mined by titration, were 6.97S 0.01 (Gln-LNA) and 7.57S0.05
(Glu-LNA).
Table 1
Kinetic parameters for conversion of N-terminally Gln-containing
peptides by recombinant human QC in bu¡er solution containing
1% DMSO
Peptide KM (WM) kcat (s31) kcat/KM (mM31 s31)
Gln3-AL(3^11)a 87S 3a 55S 1a 632S 10a
Gln3-AL(3^11)a 155S 4 41.4S 0.4 267S 4
Gln3-AL(3^21)a 162S 12 62S 3 383S 10
Gln3-AL(3^40) 89S 10 40S 2 449S 28
Glucagon(3^29) 19S 1 10S 0.2 526S 17
aDetermined in the absence of DMSO.
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ceivable. Here, we have shown that papaya and human QC
catalyze both glutaminyl and glutamyl cyclization (Schemes 1
and 2, Figs. 1^3).
Investigating the pH dependence, we found the unproto-
nated N-terminus essential for the cyclization of Gln1 pep-
tides. Accordingly, the pKa value of the substrate was identi-
cal to the pKa value for QC catalysis (see Fig. 3 and [29]),
supporting that QC stabilizes the nucleophilic attack of the
unprotonated K-amino moiety on the amidated Q-carbonyl
carbon (Scheme 1). In contrast to the monovalent charge
present on N-terminal glutamine-containing peptides, the N-
terminal Glu residue in Glu-containing peptides is predomi-
nantly bivalently charged around neutral pH. Glutamate ex-
hibits pKa values of about 4.2 and 7.5 for the Q-carboxylic and
the K-amino moiety, respectively; i.e. at neutral pH and
above, although the K-amino nitrogen is partially or fully
unprotonated and nucleophilic, the Q-carboxylic group is neg-
atively charged, so exercising no electrophilic carbonyl activ-
ity. However, in the pH range of about 5.2^6.5, between their
respective pKa values, the two groups are present both par-
tially non-ionized, in concentrations less than 10% of the total
N-terminal Glu-containing peptide; i.e. if the Q-carboxylic
group is protonated, the carbonyl carbon is electrophilic
enough to allow nucleophilic attack by the unprotonated K-
amino group. According to the Henderson^Hasselbalch equa-
tion, the concentration of the uncharged molecule species is
about 0.05% of the total substrate at pH 6.0. Only in these
molecules the hydroxyl ion can serve as a leaving group
(Scheme 2). These assumptions are corroborated by the pH
dependence data obtained for the QC-catalyzed conversion of
Glu-LNA. In contrast to glutamine conversion of Gln-LNA
by QC, the pH optimum of catalysis shifts to the acidic range.
Furthermore, the kinetically determined pKa value of
7.55S 0.02 is in excellent agreement with that of the K-amino
group of Glu-LNA, determined by titration (7.57S 0.05).
There was no non-enzymatic turnover of Glu-LNA, which
agrees with the observed negligible pGlu peptide formation.
The conclusion from these data is that in vivo only enzymatic
transformation of N-terminal Glu seems conceivable. In vitro,
applying inhibitors of QC and EC activity, we were able to
suppress both reactions (Figs. 1 and 2).
Physiologically, AL can be generated either directly on the
plasma membrane or during endosomal recycling or in the
endoplasmic reticulum (ER), the trans-Golgi network or with-
in secretory vesicles [30^32]. Recently, the constitutive secre-
tory pathway providing AL has been discussed [33]. Coinci-
dentally, QC is also localized in the secretory pathway [4^7].
Although Glu-AL peptides have been found to be generated in
the ER, the Golgi network and within secretory vesicles, fur-
ther detailed cell biological work is needed to identify the
subcellular site of pGlu-AL peptide formation.
The primary biological function of QC is likely terminal
hormone maturation in endocrine cells by glutamine cycliza-
tion during the hormone secretion process. Such secretory
vesicles are known to be acidic in pH. Thus, an auxiliary
function of the enzyme in the narrow pH range from 5.0 to
7.0 could be its glutamyl cyclase activity (Scheme 2). How-
ever, due to the relatively ine⁄cient rate of Glu cyclization
compared to Gln conversion, it is questionable whether glu-
tamyl cyclization plays a signi¢cant physiological role. In the
etiology of neurodegenerative disorders, however, glutamyl
cyclization may be of relevance providing that accumulation
of peptidase-resistant substrate and appropriate QC concen-
tration and compartment acidity coincide.
Reviews of potential AD treatment do not propose inhibi-
tion of pyroglutamate formation as potential therapeutic in-
tervention [9,13,34]. Since pGlu-AL peptides appear highly
abundant, and since pGlu-AL formation prevents intracellular
aminopeptidase-mediated disposal of such improperly gener-
ated peptides [30,35], inhibition of brain QC and EC activity
could prove a valuable tool to combat the onset and progres-
sion of neurodegenerative disorders.
Whether N-terminal processing of AL-derived peptides
takes place in vivo by a combination of aminopeptidase, di-
peptidyl peptidase and glutaminyl/glutamyl cyclase activity
needs further investigation. Previously, similar N-terminal
processing in an analogous fashion was suggested for the neu-
ropeptide antho-RFamide precursors of coelenterates [36].
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